Two specific questions we could not address due to the whole-tumour microarray data we used were: 1) which cells were expressing inhibitory molecules and 2) whether our results would have been different had we included “missing” relevant molecules from the transcriptomics data, e.g., the immune checkpoint CTLA-4. The gene discussed is CTLA4; the disease is neoplasm.